Federal appeals court to consider Louisiana’s arguments for banning telehealth abortion
The case could affect telehealth access to mifepristone nationwide, with about 91,000 abortions last year provided by mail in states with bans, Guttmacher said.
- On Wednesday, the 5th Circuit Court of Appeals will hear Louisiana's challenge to the FDA's telehealth abortion rule, with oral arguments livestreamed at 9 a.m. CDT.
- Louisiana argues the FDA rule violates the Dobbs v. Jackson Women's Health Organization decision by allowing mail-order abortion access in states that have banned the procedure.
- The Guttmacher Institute reported about 91,000 abortions were provided via telehealth last year, while Alliance Defending Freedom aims to prove Louisiana has proper standing to challenge the policy.
- Abortion law expert Mary Ziegler expects the conservative Circuit Court to side with Louisiana, noting the ruling will likely serve as a roadmap for a final Supreme Court decision.
- The Biden-era policy remains in effect while similar legal battles continue in Missouri and Texas; Melissa Grant warns the challenge threatens access across all 50 states.
11 Articles
11 Articles
Louisiana et al. v. Food and Drug Administration: A case working its way through federal courts poses a dangerous threat to abortion access nationwide.
A significant case1 currently progressing through federal courts poses one of the most formidable threats to abortion access since the overturning of Roe v. Wade. In Louisiana et al. v. Food and Drug Administration, Louisiana seeks to impose its anti-abortion policies on states nationwide, and the outcome of this case may dictate whether individuals can access […]
Federal appeals court to consider Louisiana’s arguments for banning telehealth abortion • Oklahoma Voice
Next week, the U.S. 5th Circuit Court of Appeals will consider Louisiana’s arguments for tightening federal policy around a common abortion and miscarriage drug. The primary target of Louisiana v. Food and Drug Administration and similar lawsuits against mifepristone is to end a Biden-era policy allowing abortion pills to be prescribed without an in-person visit with a provider.
Coverage Details
Bias Distribution
- 91% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
